Drug Trial Radar · NCT06707987
Post-registration Trial of the Non-immunogenic Staphylokinase in Acute Ischemic Stroke (FORPI Registry)
Last checked: Nov 20, 2026Latest source record: Dec 5, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
23,250
Actual
Start
Mar 1, 2021
Primary completion
Dec 31, 2024
Study completion Feb 1, 2025
Sponsor
- Lead sponsor
- Supergene, LLCIndustry
- Sponsor type
- Industry
- Collaborators
- Federal Center of Cerebrovascular Pathology and Stroke, Russian Federation Ministry of Health
- First posted
- Nov 27, 2024
Design
- Study type
- Observational
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The aim of FORPI Registry is to study the safety and efficacy of the non-immunogenic staphylokinase in patients with acute ischemic stroke in routine clinical practice.
Conditions
- Acute Ischemic Stroke
Interventions
Non-immunogenic staphylokinaseDrug
Drug: non-immunogenic staphylokinase 10 mg as a single intravenous bolus Other Names: Fortelyzin®
Primary outcomes
What the sponsor says the trial is designed to measure.
- Modified Rankin Scale (mRS) score of 0-2 on day 90 after drug administrationTime frame: day 90 after drug administration
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Federal Brain and Neurotechnology Center
Moscow, Russia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.